Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biocardia Inc (BCDA)

Biocardia Inc (BCDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,690
  • Shares Outstanding, K 10,940
  • Annual Sales, $ 60 K
  • Annual Income, $ -7,950 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta 0.60
  • Price/Sales 27.06
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.17
  • Number of Estimates 1
  • High Estimate -0.17
  • Low Estimate -0.17
  • Prior Year -0.59
  • Growth Rate Est. (year over year) +71.19%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1201 +3.56%
on 03/24/26
1.4100 -17.73%
on 03/17/26
-0.1300 (-10.08%)
since 02/27/26
3-Month
1.0900 +6.42%
on 02/04/26
1.4300 -18.88%
on 01/20/26
-0.1100 (-8.66%)
since 12/26/25
52-Week
1.0000 +16.00%
on 09/18/25
3.2000 -63.75%
on 04/29/25
-1.5200 (-56.72%)
since 03/27/25

Most Recent Stories

More News
BioCardia Reports 2025 Business Highlights and Financial Results

SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc.  [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 1.1600 (-1.69%)
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 1.1600 (-1.69%)
BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA

SUNNYVALE, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ: BCDA] , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 1.1600 (-1.69%)
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)

SUNNYVALE, Calif., March 03, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc.  [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 1.1600 (-1.69%)
BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart

SUNNYVALE, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc.  [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 1.1600 (-1.69%)
BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)

SUNNYVALE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ: BCDA] , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 1.1600 (-1.69%)
BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

SUNNYVALE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ: BCDA] , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 1.1600 (-1.69%)
BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno

SUNNYVALE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 1.1600 (-1.69%)
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

SUNNYVALE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 1.1600 (-1.69%)
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

SUNNYVALE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA] , a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 1.1600 (-1.69%)

Business Summary

BioCardia Inc. is engaged in developing regenerative biologic therapies to treat cardiovascular disease. The company's product candidate consists of CardiAMP(TM), CardiALLO(TM) and Helix Biotherapeutic Delivery System(TM) in clinical development stage. BioCardia Inc. is headquartered in San Carlos, California....

See More

Key Turning Points

3rd Resistance Point 1.2765
2nd Resistance Point 1.2532
1st Resistance Point 1.2066
Last Price 1.1600
1st Support Level 1.1367
2nd Support Level 1.1134
3rd Support Level 1.0668

See More

52-Week High 3.2000
Fibonacci 61.8% 2.3596
Fibonacci 50% 2.1000
Fibonacci 38.2% 1.8404
Last Price 1.1600
52-Week Low 1.0000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.